Endurance Wealth Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Endurance Wealth Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-399	Closed	-$10K	–	493
2016 Q3	$10K	Hold	399	–	–	﹤0.01%	392
2016 Q2	$9K	Sell	399 -1,200	-75%	-$31.4K	﹤0.01%	389
2016 Q1	$47	Hold	1,599	–	–	0.01%	266
2015 Q4	$53K	Hold	1,599	–	–	0.01%	252
2015 Q3	$61K	Sell	1,599 -1,000	-38%	-$42.9K	0.01%	250
2015 Q2	$117K	Buy	2,599 +2,200	+551%	+$85.6K	0.02%	204
2015 Q1	$12K	Buy	+399	New	+$15.5K	﹤0.01%	187

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Endurance Wealth Management's ENTA Position: Q4 2016 in Review

Endurance Wealth Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2016, closing a stake of 399 shares — an estimated $10K sold.

Endurance Wealth Management first reported a position in ENTA in Q1 2015 and held it in 7 quarters. The position peaked at $117K in Q2 2015. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

Endurance Wealth Management reported no remaining Enanta Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Endurance Wealth Management sold 399 Enanta Pharmaceuticals shares in Q4 2016, an estimated $10K.
Endurance Wealth Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 7 quarters.
Endurance Wealth Management's Enanta Pharmaceuticals position peaked at $117K in Q2 2015.
149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on Endurance Wealth Management's 13F filing for Q4 2016, filed 12 Jan 2017.